EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis

Hanna K Bredin, Camilla Krakstad, Erling A Hoivik

PLOS ONE · 21.03.2023 · 18 (3) · e0283203

DOI: 10.1371/journal.pone.0283203 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 21.03.2023. Verfasst von Hanna K Bredin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Endometrial Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kreftforeningen, Norges Forskningsråd, Universitetet i Bergen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several studies have highlighted the frequent alterations of the PI3K pathway in endometrial cancer leading to increased signaling activation with potential for targeted treatment. The objective of this meta-study was to evaluate how PIK3CA exon 9/20 mutations affect survival in endometrial cancer patients, based on available literature. Topic-based search strategies were applied to databases including CENTRAL, MEDLINE, Embase, Web of Science and COSMIC. All studies assessing the impact of mutations in exon 9 and exon 20 of PIK3CA on survival rates of endometrial cancer patients were selected for inclusion. Statistical meta-analysis was performed with the ‘ meta’ package in RStudio. Overall, 7 of 612 screened articles were included in the present study, comprising 1098 women with endometrial cancer. Meta-analysis revealed a tendency of impaired survival for patients with PIK3CA exon 9 and/or exon 20 mutations (RR 1.28; 95% CI 0.84, 1.94; p = 0.25). This tendency was consistent in subgroup analyses stratified by histologic type or -grade, with the most prominent effect in low-grade endometrial cancers (RR 2.04; 95% CI 0.90, 4.62; p = 0.09). In summary, these results suggest that PIK3CA mutations negatively influence survival outcomes of patients with endometrial cancer, including those with low-grade tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylinositol 3-KinasesEndometrial NeoplasmsHumansFemaleSignal TransductionMutationClass I Phosphatidylinositol 3-Kinases

Substanzen

Phosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-KinasesPIK3CA protein, human

Autor:innen und Institutionen

  • Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.
  • Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.

Förderung

  • Kreftforeningen
  • Norges Forskningsråd
  • Universitetet i Bergen

Zitieren

APA

Bredin, H. K., Krakstad, C., & Hoivik, E. A. (2023). PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis. PLOS ONE, 18(3), e0283203. https://doi.org/10.1371/journal.pone.0283203

Vancouver

Bredin HK, Krakstad C, Hoivik EA. PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis. PLOS ONE. 2023;18(3):e0283203. doi:10.1371/journal.pone.0283203

BibTeX
@article{Bredin2023,
  author = {Bredin, Hanna K and Krakstad, Camilla and Hoivik, Erling A},
  title = {PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {3},
  pages = {e0283203},
  doi = {10.1371/journal.pone.0283203}
}
Kostenlos starten →